Skip to main content
SpringerLink
Log in
Book cover

Hämostaseologie pp 461–510Cite as

Arterielle Thromboembolien

  • Chapter

  • 4504 Accesses

Zusammenfassung

Der Begriff Atherothrombose beschreibt die Kombination aus akuten und chronischen Ereignissen in erkrankten arteriellen Gefäßen und stellt derzeit v. a. in den westlichen Ländern die hauptsächliche Ursache für Morbidität und Mortalität dar. Frühes Erkennen und Risikostratifizierung sind nach wie vor ein wichtiger Bestandteil der Prävention der Atherosklerose und ihrer Komplikationen. Neben klassischen Risikofaktoren sind in den letzten Jahren verschiedene Messparameter erarbeitet worden, die einen gesicherten oder möglichen prognostischen Faktor für Aspekte der Atherothrombose darstellen. Eine weitere wichtige Ursache für Thromboembolien im arteriellen System, v. a. bei jungen Patienten, stellt ein persistierendes Foramen ovale (PFO) dar, das zu einem Rechts-links-Shunt und damit zum übertreten von thrombotischem Material in den aortalen Kreislauf führen kann.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   229.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Bhatt DL, Steg PG, Ohman EM et al. (2006) International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295: 180–9.

    Article  CAS  PubMed  Google Scholar 

  • Bigalke B, Lindemann S, Ehlers R et al. (2006) Expression of platelet collagen receptor glycoprotein VI is associated with acute coronary syndrome. Eur Heart J 27: 2165–9

    Article  CAS  PubMed  Google Scholar 

  • Blankenberg S, McQueen MJ, Smieja M et al. (2006) Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 114: 201–8

    Article  CAS  PubMed  Google Scholar 

  • Bogousslavsky J, Garazi S, Jeanrenaud X et al. (1996) Stroke recurrence in patients with patent foramen ovale: the Lausanne Study. Lausanne Stroke with Paradoxal Embolism Study Group. Neurology 46: 1301–5

    CAS  PubMed  Google Scholar 

  • Cujec B, Mainra R, Johnson DH (1999) Prevention of recurrent cerebral ischemic events in patients with patent foramen ovale and cryptogenic strokes or transient ischemic attacks. Can J Cardiol 15: 57–64

    CAS  PubMed  Google Scholar 

  • Folsom AR, Chambless LE, Ballantyne CM et al. (2006) An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med 166: 1368–73

    Article  CAS  PubMed  Google Scholar 

  • Gawaz M, Langer H, May AE (2005) Platelets in inflammation and atherogenesis. J Clin Invest 115: 3378–84

    Article  CAS  PubMed  Google Scholar 

  • Healy AM, Pickard MD, Pradhan AD et al. (2006) Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation 113: 2278–84

    Article  CAS  PubMed  Google Scholar 

  • Homma S, Sacco RL, Di Tullio MR et al. (2002) Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation 105: 2625–31

    Article  PubMed  Google Scholar 

  • Khairy P, O’Donnell CP, Landzberg MJ (2003) Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review. Ann Intern Med 139: 753–60

    PubMed  Google Scholar 

  • Kizer JR, Devereux RB (2005) Clinical practice. Patent foramen ovale in young adults with unexplained stroke. N Engl J Med 353: 2361–72

    Article  CAS  PubMed  Google Scholar 

  • Mattace-Raso FU, van der Cammen TJ, Hofman A et al. (2006) Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation 113: 657–63

    Article  PubMed  Google Scholar 

  • O’Hare AM, Katz R, Shlipak MG et al. (2006) Mortality and cardiovascular risk across the ankle-arm index spectrum: results from the Cardiovascular Health Study. Circulation 113: 388–93

    Article  PubMed  Google Scholar 

  • Orgera MA, O’Malley PG, Taylor AJ (2001) Secondary prevention of cerebral ischemia in patent foramen ovale: systematic review and meta-analysis. South Med J 94: 699–703

    CAS  PubMed  Google Scholar 

  • Redgrave JN, Lovett JK, Gallagher PJ et al. (2006) Histological assessment of 526 symptomatic carotid plaques in relation to the nature and timing of ischemic symptoms: the Oxford plaque study. Circulation 113: 2320–8

    Article  CAS  PubMed  Google Scholar 

  • Ruggeri ZM (2002) Platelets in atherothrombosis. Nat Med 8: 1227–34

    Article  CAS  PubMed  Google Scholar 

  • Sanz J, Moreno PR, Fuster V (2007) The year in atherothrombosis. J Am Coll Cardiol 49: 1740–9

    Article  PubMed  Google Scholar 

  • Sattar N, Wannamethee G, Sarwar N et al. (2006) Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 114: 623–9

    Article  CAS  PubMed  Google Scholar 

  • Schnabel R, Lubos E, Rupprecht HJ et al. (2006) B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: results from the AtheroGene study. J Am Coll Cardiol 47: 552–8

    Article  CAS  PubMed  Google Scholar 

  • Smith A, Patterson C, Yarnell J et al. (2005) Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation 112: 3080–7

    Article  PubMed  Google Scholar 

  • Werner N, Kosiol S, Schiegl T et al. (2005) Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353: 999–1007

    Article  CAS  PubMed  Google Scholar 

  • Wilson PW, D’Agostino RB, Levy D et al. (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97: 1837–47

    CAS  PubMed  Google Scholar 

  • Yusuf S, Hawken S, Ounpuu S et al. (2005) Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a casecontrol study. Lancet 366: 1640–9

    Article  PubMed  Google Scholar 

Literatur

  • Alessi MC, Juhan-Vague I (2006) PAI-1 and the metabolic syndrome — Links, causes, and consequences. Arterioscler Thromb Vascular Biol 26(10): 2200–7

    Article  CAS  Google Scholar 

  • Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T et al. (2006) Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Eng J Med 354(15): 1578–88

    Article  CAS  Google Scholar 

  • Brey RL (2004) Management of the neurological manifestations of APS — what do the trials tell us? Thrombosis Research 114(5–6): 489–99

    Article  CAS  PubMed  Google Scholar 

  • Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P et al. (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period — A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine 82(5): 299–308

    Article  PubMed  Google Scholar 

  • Cervera R, Piette JC, Font J, Khamashta MA, Cervera R, Piette JC et al. (2002) Antiphospholipid syndrome — Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis and Rheumatism 46(4): 1019–27

    Article  PubMed  Google Scholar 

  • Chen YQ, Su M, Walia RR, Hao Q, Covington JW, Vaughan DE (1998) Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. J Biol Chem 273(14): 8225–31

    Article  CAS  PubMed  Google Scholar 

  • Clarke R, Collins R, Lewington S, Donald A, Alfthan G, Tuomilehto J et al. (2002) Homocysteine and risk of ischemic heart disease and stroke — A meta-analysis. Jama 288(16): 2015–22

    Article  CAS  Google Scholar 

  • Colman RW (2006) Are hemostasis and thrombosis two sides of the same coin? J Exper Med 203(3): 493–5

    Article  CAS  Google Scholar 

  • Cushman M, Lemaitre RN, Kuller LH, Psaty BM, Macy EM, Sharrett AR et al. (1999) Fibrinolytic activation markers predict myocardial infarction in the elderly — The cardiovascular health study. Arterioscler Thromb Vascular Biol 19(3): 493–8

    CAS  Google Scholar 

  • Dawson S, Hamsten A, Wiman B, Henney A, Humphries S (1991) Genetic-Variation at the Plasminogen-Activator Inhibitor-1 Locus Is Associated with Altered Levels of Plasma Plasminogen-Activator Inhibitor-1 Activity. Arteriosclerosis and Thrombosis 11(1): 183–90

    CAS  PubMed  Google Scholar 

  • De Groot PG, Derksen RHMW (2005) The antiphospholipid syndrome: clinical characteristics, laboratory features and pathogenesis. Current Opinion in Infectious Diseases 18(3): 205–10

    Article  PubMed  Google Scholar 

  • Eldibany MM, Caprini JA (2007) Hyperhomocysteinemia and thrombosis — An overview. Archives of Pathology & Laboratory Medicine 131(6): 872–84

    CAS  Google Scholar 

  • Endler G, Marsik C, Jilma B, Schickbauer T, Quehenberger P, Mannhalter C (2007) Evidence of a U-shaped association between factor XII activity and overall survival. J Thrombosis Haemostasis 5(6): 1143–8

    Article  CAS  Google Scholar 

  • Eriksson P, Kallin B, Vanthooft FM, Bavenholm P, Hamsten A (1995) Allele-Specific Increase in Basal Transcription of the Plasminogen-Activator Inhibitor-1 Gene Is Associated with Myocardial-Infarction. Proceedings of the National Academy of Sciences of the United States of America 14; 92(6): 1851–5

    Article  Google Scholar 

  • Feinbloom D, Bauer KA (2005) Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arterioscler Thromb Vascular Biol 25(10): 2043–53

    Article  CAS  Google Scholar 

  • Festa A, D’Agostino R, Tracy RP, Haffner SM (2002) Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes — The insulin resistance atherosclerosis study. Diabetes 51(4): 1131–7

    Article  CAS  PubMed  Google Scholar 

  • Gailani D, Renne T (2007) Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vascular Biol 27(12): 2507–13

    Article  CAS  Google Scholar 

  • Galli M (2003) Antiphospholipid syndrome: Association between laboratory tests and clinical practice. Pathophysiology of Haemostasis and Thrombosis 33(5–6): 249–55

    Article  PubMed  Google Scholar 

  • Galli M (2005) Pathogenesis of antiphospholipid syndrome. Thrombosis Research 115: 103–7

    PubMed  Google Scholar 

  • Galli M, Luciani D, Bertolini G, Barbui T (2003) Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101(5): 1827–32

    Article  CAS  PubMed  Google Scholar 

  • Giannakopoulos B, Passam F, Rahgozar S, Krilis SA (2007) Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 109(2): 422–30

    Article  CAS  PubMed  Google Scholar 

  • Ginsburg D (2005) Genetic Risk Factors for Arterial Thrombosis and Inflammation. Hematology p 442–4

    Google Scholar 

  • Girolami A, Randi ML, Gavasso S, Lombardi AM, Spiezia F (2004) The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: A study of prevalence in 21 patients and review of the literature. J Thrombosis Thrombolysis 17(2): 139–43

    Article  CAS  Google Scholar 

  • Govers-Riemslag JWP, Smid M, Cooper JA, Bauer KA, Rosenberg RD, Hack CE et al. (2007) The plasma kallikrein-kinin system and risk of cardiovascular disease in men. J Thrombosis Haemostasis 5(9): 1896–903

    Article  CAS  Google Scholar 

  • Green D (2003) Thrombophilia and Stroke. Topics in Stroke Rehabilitation 10(3): 21–33

    Article  PubMed  Google Scholar 

  • Halleux CM, Declerck PJ, Tran SL, Detry R, Brichard SM (1999) Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: Stimulation by glucocorticoids and inhibition by catecholamines. J Clin Endocrinol Metabolism 84(11): 4097–105

    Article  CAS  Google Scholar 

  • Healy AM, Gelehrter TD (1994) Induction of Plasminogen-Activator Inhibitor-1 in Hepg2 Human Hepatoma-Cells by Mediators of the Acute-Phase Response. J Biol Chem 269(29): 19095–100

    CAS  PubMed  Google Scholar 

  • Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L et al. (1999) Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nature Medicine 5(10):1135–42

    Article  CAS  PubMed  Google Scholar 

  • Iacoviello L, Burzotta F, Di Castelnuovo A, Zito F, Marchioli R, Donati MB (1998). The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: A meta-analysis. Thrombosis and Haemostasis 80(6): 1029–30

    CAS  PubMed  Google Scholar 

  • Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B, Hallmans G (2000) Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke 31(1): 26–32

    CAS  PubMed  Google Scholar 

  • Kohler HP, Grant PJ (2000) Mechanisms of disease: Plasminogen-activator inhibitor type 1 and coronary artery disease. N Eng J Med 342(24): 1792–801

    Article  CAS  Google Scholar 

  • Koster T, Rosendaal FR, Briet E, Vandenbroucke JP (1994) John Hageman’s factor and deep-Vein thrombosis: Leiden Thrombophilia Study. Brit J Haematol 87(2): 422–4

    Article  CAS  Google Scholar 

  • Ladenvall P, Johansson L, Jansson JH, Jern S, Nilsson TK, Tjarnlund A et al. (2002) Tissue-type plasminogen activator-7,351 C/T enhancer polymorphism is associated with a first myocardial infarction. Thrombosis and Haemostasis 87(1): 105–9

    CAS  PubMed  Google Scholar 

  • Lane DA, Grant PJ (2000) Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 95(5): 1517–32

    CAS  PubMed  Google Scholar 

  • Levine JS, Branch DW, Rauch J (2002) Medical progress: The antiphospholipid syndrome. N Eng J Med 346(10): 752–63

    Article  CAS  Google Scholar 

  • Libby P, Theroux P (2005) Pathophysiology of coronary artery disease. Circulation 111(25): 3481–8

    Article  PubMed  Google Scholar 

  • Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M et al. (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. N Eng J Med 354(15): 1567–77

    Article  CAS  Google Scholar 

  • Loscalzo J (2006) Homocysteine trials — Clear outcomes for complex reasons. N Eng J Med 354(15): 1629–32

    Article  CAS  Google Scholar 

  • Lundblad D, Dinesen B, Rautio A, Roder ME, Eliasson M (2005) Low level of tissue plasminogen activator activity in non-diabetic patients with a first myocardial infarction. J Intern Med 258(1): 13–20

    Article  CAS  PubMed  Google Scholar 

  • Mammen EF (1999) Sticky platelet syndrome. Seminars in Thrombosis and Hemostasis 25(4): 361–5

    Article  CAS  PubMed  Google Scholar 

  • Mannucci PM, Bernardinelli L, Foco L, Galli M, Ribichini F, Tubaro M et al. (2005) Tissue plasminogen activator antigen is strongly associated with myocardial infarction in young women. J Thrombosis Haemostasis 3(2): 280–6

    Article  CAS  Google Scholar 

  • Mannucci PM, Merlini PA, Ardissino D, Barzuini C, Bernardi F, Bernardinelli L et al. (2003) No evidence of association between prothrombotic gene Polymorphisms and the development of acute myocardial infarction at a young age. Circulation 107(8): 1117–22

    Article  Google Scholar 

  • Martinelli I (2005) von Willebrand factor and factor VIII as risk factors for arterial and venous thrombosis. Seminars in Hematology 42(1): 49–55

    Article  CAS  PubMed  Google Scholar 

  • Melchor JP, Strickland S (2005) Tissue plasminogen activator in central nervous system physiology and pathology. Thrombosis and Haemostasis 93(4): 655–60

    CAS  PubMed  Google Scholar 

  • Meltzer ME, Doggen CJM, De Groot PG, Rosendaal FR, Lisman T (2007) Fibrinolysis and the risk of venous and arterial thrombosis. Current Opinion in Hematology 14(3): 242–8

    Article  CAS  PubMed  Google Scholar 

  • Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al. (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thrombosis Haemostasis 4(2): 295–306

    Article  CAS  Google Scholar 

  • Ortel TL (2005) Thrombosis and the Antiphospholipid Syndrome. Hematology p 462–8

    Google Scholar 

  • Reitsma PH (2004) Is hypercoagulability an issue in arterial thrombosis? No. J Thrombosis Haemostasis 2(5): 692–4

    Article  CAS  Google Scholar 

  • Ross R (1999) Mechanisms of disease — Atherosclerosis — An inflammatory disease. N Eng J Med 340(2): 115–26

    Article  CAS  Google Scholar 

  • Salomon O, Steinberg DM, Dardik R, Rosenberg N, Zivelin A, Tamarin I et al. (2003) Inherited factor XI deficiency confers no protection against acute myocardial infarction. J Haemostasis 1(4): 658–61

    Article  CAS  Google Scholar 

  • Schousboe I (2008) Pharmacological regulation of factor XII activation may be a new target to control pathological coagulation. Biological Pharmacology 75(5): 1007–1013

    Article  CAS  Google Scholar 

  • Smith A, Patterson C, Yarnell J, Rumley A, Ben-Shlomo Y, Lowe G (2005) Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation 112(20): 3080–7

    Article  PubMed  Google Scholar 

  • Smith SA, Mutch NJ, Baskar D, Rohloff P, Docampo R, Morrissey JH (2006) Polyphosphate modulates blood coagulation and fibrinolysis. Proceedings of the National Academy of Sciences of the United States of America 103(4): 903–8

    Article  CAS  PubMed  Google Scholar 

  • Takazoe K, Ogawa H, Yasue H, Sakamoto T, Soejima H, Miyao Y et al. (2001) Increased plasminogen activator inhibitor activity and diabetes predict subsequent coronary events in patients with angina pectoris. Annals of Medicine 33(3): 206–12

    Article  CAS  PubMed  Google Scholar 

  • Thogersen AM, Soderberg S, Jansson JH, Dahlen G, Boman K, Nilsson TK et al. (2004) Interactions between fibrinolysis, lipoproteins and leptin related to a first myocardial infarction. Europ J Cardiovasc Prevention Rehabil 11(1): 33–40

    Article  Google Scholar 

  • Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ et al. (2004) Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death — The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. Jama 291(5): 565–75

    Article  CAS  PubMed  Google Scholar 

  • Vaughan DE, Lazos SA, Tong K (1995) Angiotensin-Ii Regulates the Expression of Plasminogen-Activator Inhibitor-1 in Cultured Endothelial-Cells — A Potential Link Between the Renin-Angiotensin System and Thrombosis. J Clin Invest 95(3): 995–1001

    Article  CAS  PubMed  Google Scholar 

  • Voetsch B, Loscalzo J (2004) Genetic determinants of arterial thrombosis. Arterioscler Thromb Vascular Biol 24(2): 216–29

    Article  CAS  Google Scholar 

  • Wald DS, Law M, Morris JK (2002) Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Brit Med J 325(7374): 1202–1206K

    Article  PubMed  Google Scholar 

  • Wiman B, Andersson T, Hallqvist J, Reuterwall C, Ahlbom A, deFaire U (2000) Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vascular Biol 20(8): 2019–23

    CAS  Google Scholar 

  • Zeerleder S, Schloesser M, Redondo M, Wuillemin WA, Engel W, Furlan M et al. (1999) Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency — A study on 73 subjects from 14 Swiss families. Thrombosis and Haemostasis 82(4): 1240–6

    CAS  PubMed  Google Scholar 

  • Zorio E, Castello R, Falco C, Espana F, Osa A, Almenar L et al. (2003) Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system. Brit J Haematol 122(6): 958–65

    Article  CAS  Google Scholar 

  • Zotz RB, Klein M, Dauben HP, Moser C, Gams E, Scharf RE (2000) Prospective analysis after coronary-artery bypass grafting: platelet GP IIIa polymorphism (HPA-1b/PIA2) is a risk factor for bypass occlusion, myocardial infarction, and death. Thromb Haemost 83(3): 404–7

    CAS  PubMed  Google Scholar 

  • Zotz RB, Scharf RE (2002) Platelet Receptor Polymorphisms and their Role in Cardiovascular Disease. Laboratoriumsmedizin/J Lab Med 26(11–12): 584–93

    CAS  Google Scholar 

  • Zotz RB, Winkelmann BR, Muller C, Boehm BO, Marz W, Scharf RE (2005) Association of polymorphisms of platelet membrane integrins alpha IIb beta 3 (HPA-1b/Pl(A2)) and alpha(2)beta(1) (alpha(2)807TT) with premature myocardial infarction. J Thrombosis Haemostasis 3(7): 1522–9

    Article  CAS  Google Scholar 

Literatur

  • Antithrombotic Trialists’Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324: 71–86

    Article  Google Scholar 

  • Arca M, Gaspardone A (2007) Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events. Drugs 67,Suppl 1: 29–42

    Article  CAS  PubMed  Google Scholar 

  • Bhatt DL, Fox KAA, Werner ChB et al. (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354: 1706–1717

    Article  CAS  PubMed  Google Scholar 

  • Diener HC, Sacco RL, Yusuf S et al; Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study group (2008) Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a doubleblind, active and placebo-controlled study. Lancet Neurol 7: 875–884. Erratum in: Lancet Neurol 2008;7(11): 985

    Article  CAS  PubMed  Google Scholar 

  • CARS-Investigators (1997) Randomised double-blind trial of fixed lowdose warfarin with aspirin after myocardial infarction. Lancet 350: 389–396

    Article  Google Scholar 

  • Catella-Lawson F, Reilly MP, Kapoor SC et al. (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345: 1809–1817

    Article  CAS  PubMed  Google Scholar 

  • CURE-Trial Investigators (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345: 494–502

    Article  Google Scholar 

  • Diener HC, Cunha L, Forbes C et al. (1996) European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143: 1–13

    Article  CAS  PubMed  Google Scholar 

  • Diener HC, Bogousslavsky J, Brass LM et al. on behalf of the MATCH investigators (2004) Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet 364: 331–337

    Article  CAS  PubMed  Google Scholar 

  • (The) ESPRIT-Study Group (2006) Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367: 1665–1673

    Article  CAS  Google Scholar 

  • Frilling B, Schiele R, Gitt AK et al. (2001) Characterization and clinical course of patients not receiving aspirin for acute myocardial infarction: results from the MITRA and MIR studies. Am Heart J 141: 200–205

    Article  CAS  PubMed  Google Scholar 

  • Gawaz M (2004) Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 61: 498–511

    Article  CAS  PubMed  Google Scholar 

  • Geisler T, Graß D, Bigalke B et al. (2008) The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 6: 54–61

    CAS  PubMed  Google Scholar 

  • Gent M and CAPRIE Steering Committee (1996) A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329–1339

    Article  CAS  Google Scholar 

  • Helin-Salminvaara A, Virtanen A, Vesalainen R et al. (2006) NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 27: 1657–1663

    Article  Google Scholar 

  • Hennekens CH, Sacks FM, Tonkin A et al. (2004) Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses. Arch Int Med 164: 40–44

    Article  CAS  Google Scholar 

  • Hohlfeld T, Zimmermann N, Weber A-A et al. (2008) Pyrazolinone analgesics prevent the antiplatelet effect of aspirin and preserve human platelet thromboxane synthesis. J Thromb Haemost 6: 166–173

    CAS  PubMed  Google Scholar 

  • ISIS-2 (1988) Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 2: 349–360

    Google Scholar 

  • Juul-Möller S, Edvardsson N, Jahnmatz B et al. () For the Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with chronic stable angina pectoris. Lancet 1992 340: 1421–1425

    Article  PubMed  Google Scholar 

  • Kearney PM, Baigent C, Godwin J et al. (2006) Do selective cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332: 1302–1308

    Article  CAS  PubMed  Google Scholar 

  • Labinaz M, Ho C, Banerjee S et al. (2007) Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention. Can J Cardiol 23: 963–970

    CAS  PubMed  Google Scholar 

  • Laufs U, Liao JK (2000) Targeting Rho in cardiovascular disease. Circ Res 87: 526–528

    CAS  PubMed  Google Scholar 

  • Massberg S, Schulz C, Gawaz M (2003) Role of platelets in the pathophysiology of acute coronary syndrome. Sem Vasc Med 3: 147–162

    Article  Google Scholar 

  • Mac Donald TM, Wei L (2003) Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361: 573–574

    Article  CAS  Google Scholar 

  • (The) Medical Research Council’s General Practice Research Framework (1998) Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 351: 233–241

    Article  Google Scholar 

  • McAlister FA, Ghali WA, Gong Y et al. (2006) Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure. Circulation 113: 2572–2578

    Article  PubMed  Google Scholar 

  • O’Regan C, Wu P, Arora P et al. (2008) Statin therapy in stroke prevention: a metaanalysis involving 121,000 patients. Am J Med 121: 24–33

    Article  CAS  Google Scholar 

  • Patrono C, Coller B, Dalen JE et al. (2001) Platelet-active drugs. The relationship among dose, effectiveness, and side effects. Chest 119: 39S–63S

    Article  CAS  PubMed  Google Scholar 

  • Sacks FM, Pfeffer MA, Moye LA et al. for the Cholesterol and Recurrent Events Trial Investigators (CARE) (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335: 1001–1009

    Article  CAS  PubMed  Google Scholar 

  • Schrör K. Mehta P, Mehta JL (2005) Cardiovascular risk of selective cyclooxygenase-2-inhibitors. J Cardiovasc Pharmacol Ther 10: 95–101

    Article  PubMed  Google Scholar 

  • Siller-Matula J, Schrör K, Wojta J, Huber K (2007) Thienopyridines in cardiovascular disease: Focus on clopidogrel resistance. Thromb Haemost 97: 385–393

    CAS  PubMed  Google Scholar 

  • Spencer FA, Santopinto JJ, Gore JM, Goldberg RJ et al. (2002) Impact of aspirin on presentation and hospital outcomes in patients with acute coronary syndromes (The Global Registry of acute Coronary Events [GRACE]). Am J Cardiol 90: 1056–1061

    Article  CAS  PubMed  Google Scholar 

  • Steering Committee of the Physicians’ Health Study Research Group (1989) Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 321: 129–13

    Google Scholar 

  • Stys T, Lawson WE, Smaldone GC, Stys A (2000) Does aspirin attenuate the beneficial effects of angiotensin-converting enzyme inhibition in heart failure? Arch Int Med 160: 1409–1413

    Article  CAS  Google Scholar 

Literatur

  • Adams HP, del Zoppo G, Alberts MJ et al. (2007) Guidelines for the early management of adults with ischemic stroke. Stroke 38: 1655–1711

    Article  PubMed  Google Scholar 

  • Adams RJ, Albers G, Alberts MJ et al. (2008) Update to the AHA/ASA Recommendations for the prevention of stroke in patients with stroke and transient ischemic attacks. Stroke 39: 1647–1652

    Article  PubMed  Google Scholar 

  • Albers G et al. (2006) Guidelines for the prevention of stroke in patients with ischemic stroke or transient ischemic attacks. Circulation 113: e409–e449

    Article  PubMed  Google Scholar 

  • Amarenco P, Bogousslavsky J, Callahan A 3rd et al. (2006) High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355: 549–559

    Article  CAS  PubMed  Google Scholar 

  • Amarenco P, Labreuche J, Lavallee P, Touboul PJ (2004) Statins in stroke prevention and carotid atherosclerosis: systematic review and upto-date meta-analysis. Stroke 35: 2902–2909

    Article  CAS  PubMed  Google Scholar 

  • Bhatt DL, Fox KAA, Hacke W (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354: 1706–1717

    Article  CAS  PubMed  Google Scholar 

  • Colhoun HM, Betteridge DJ, Durrington PN et al. (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364: 685–696

    Article  CAS  PubMed  Google Scholar 

  • Collins R, Peto R, MacMahon S et al. (1990) Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 335: 827–838

    Article  CAS  PubMed  Google Scholar 

  • Connolly S, Pogue J, Hart R et al. (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesatan for prevention of Vascular Events (ACTIVE-W): a randomized controlled trial. Lancet 367: 1903–1912

    Article  CAS  PubMed  Google Scholar 

  • Dahlof B, Devereux RB, Kjeldsen SE et al. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 995–1003

    Article  CAS  PubMed  Google Scholar 

  • Diener HC, Allenberg JR, Bode C et al. (2007) Leitlinien der Deutschen Gesellschaft für Neurologie und der Deutschen Schlaganfallgesellschaft zur Primär-und Sekundärprävention des Schlaganfalls. Akt Neurol 34: 8–12

    Article  Google Scholar 

  • Diener HC, Bogousslavsky J, Brass LM et al. (2004) Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364: 331–337

    Article  CAS  PubMed  Google Scholar 

  • Eames PJ, Blake MJ, Dawson SL et al. (2002) Dynamic cerebral autoregulation and beat to beat blood pressure control are impaired in acute stroke. J Neurol Neurosurg Psychiatry 72: 467–472

    CAS  PubMed  Google Scholar 

  • Esprit study group (2006) Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomized controlled trial. Lancet 367: 1665–1673

    Article  CAS  Google Scholar 

  • Fayad P (2007) Endarterectomy and stenting for asymptomatic carotid stenosis: a race at breakneck speed. Stroke 38: 707–714

    Article  PubMed  Google Scholar 

  • Gaede P, Vedel P, Larsen N, et al. (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348: 383–393

    Article  PubMed  Google Scholar 

  • Goldstein LB, Adams R, Alberts MJ, et al. (2006) Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke 37: 1583–1633

    PubMed  Google Scholar 

  • Healy JS, Baranchuk A, Crystal E (2005) Prevention of atrial fibrillation with Angiotensin-Converting enzyme inhibitors and Angiotensin Receptor Blockers. JACC 45: 1832–1839

    Google Scholar 

  • Khaja, AM, Grotta JC (2007) Established treatments for acute ischaemic stroke. Lancet 369: 319–330

    Article  CAS  PubMed  Google Scholar 

  • Leonardi-Bee L, Bath PM, Philips SJ, Sandercock PA (2002) Blood pressure and clinical outcomes in the International Stroke Trial. Stroke 33: 1315–1320

    Article  PubMed  Google Scholar 

  • Lindholm LH, Carlberg B, Samuelsson O (2005) Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366: 1545–1553

    Article  CAS  PubMed  Google Scholar 

  • MRC/BHF (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7–22.

    Article  Google Scholar 

  • Sacco RL, Adams R, Sacco RL, Diener HC, Yusuf S (2008) Aspirin and Extended-Release Dipyridamole versus Clopidogrel for recurrent stroke. N Engl J Med 359: 1238–1251

    Article  CAS  PubMed  Google Scholar 

  • Statistisches Bundesamt (2003) Statistisches Jahrbuch. Wiesbaden: Statistisches Bundesamt

    Google Scholar 

  • Staessen JA, Wang JG, Thijs L (2001) Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 358: 1305–1315

    Article  CAS  PubMed  Google Scholar 

  • Wang X, Qin X, Demirtas H et al. (2007) Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 369: 1876–1882

    Article  CAS  PubMed  Google Scholar 

  • Weimar C, Roth MP, Zillessen G et al. (2002) Complications following acute ischemic stroke. Eur Neurol 48: 133–140

    Article  PubMed  Google Scholar 

  • Wilcox R, Bousser MG, Betteridge DJ, et al. (2007) Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events). Stroke 38: 865–873

    Article  CAS  PubMed  Google Scholar 

  • Williams B, Lacy PS, Thom SM, et al. (2006) Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113: 1213–1225

    Article  CAS  PubMed  Google Scholar 

Literatur

  • Antman EM, Cohen M, Radley D et al. (1999) Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 100: 1602–1608

    CAS  PubMed  Google Scholar 

  • ASSENT (Assessment of the Safety and Efficacy of a New Thrombolytic) Investigators (1999) Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 354: 716–722

    Article  Google Scholar 

  • ASSENT-3 (Assessment of the Safety and Efficacy of a New Thrombolytic Regimen) investigators (2001) Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 358: 605–613

    Article  Google Scholar 

  • Bassand JP, Hamm CW, Ardissino D et al.; Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology (2007). The European Society of Cardiology Task Force Guidelines for diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28(13): 1598–660

    Article  CAS  PubMed  Google Scholar 

  • Bonnefoy E, Lapostolle F, Leizorovicz A, Steg G, McFadden EP, Dubien PY, Cattan S, Boullenger E, Machecourt J (2002) Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Comparison of Angioplasty and Prehospital Thrombolysis in Acute Myocardial Infarction (CAP-TIM) study group. Lancet 360: 825–829

    Article  PubMed  Google Scholar 

  • Buse JB, Ginsberg HN, Bakris GL et al. (2007) Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association. Circulation 115: 114–126

    Article  PubMed  Google Scholar 

  • Cannon CP, Weintraub WS, Demopoulos LA et al.; for the TACTICS investigators (2001) Comparisons of early invasive and conservative strategies in patients with unstable coronary syndroms treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 344: 1879–1887

    Article  CAS  PubMed  Google Scholar 

  • CAPTURE Investigators (1997) Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 349: 1429–1435

    Article  Google Scholar 

  • Chen ZM, Jiang, LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS (2005) Addition of clopidogrel to aspirin in 45.852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366: 1607–1621

    Article  CAS  PubMed  Google Scholar 

  • Elad Y, French WJ, Shavelle DM et al. (2002) Primary angioplasty and selection bias inpatients presenting late (>12 h) after onset of chest pain and ST-elevation myocardial infarction. J Am Coll Cardiol 39: 826–833

    Article  PubMed  Google Scholar 

  • Fox KAA, Poole-Wilson PA, Henderson RA et al. (2002) Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Lancet 360: 743–751

    Article  CAS  PubMed  Google Scholar 

  • FRISC II investigators (1999) Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Fragmin and Fast Revascularisation during Instability in Coronary artery disease Investigators. Lancet 354: 708–715

    Article  Google Scholar 

  • Grines CL, Patel A, Zijlstra F et al. (2003) Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. Am Heart J 145: 47–57

    Article  CAS  PubMed  Google Scholar 

  • GUSTO III (Global Use of Strategies to Open Occluded Coronary Arteries) Investigators (1997) A comparsion of reteplase with alteplase for acute myocardial infarction. N Engl J Med 337: 1118–1123

    Article  Google Scholar 

  • GUSTO Investigators (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329: 673–682

    Article  Google Scholar 

  • Hamm CW (2004a) Akutes Koronarsyndrom. Z Kardiol 93: 72–90

    Article  CAS  PubMed  Google Scholar 

  • Hamm CW (2004b) Leitlinien: Akutes Koronarsyndrom (ACS). Teil 1: ACS ohne persitierende ST-Hebung. Z Kardiol 93: 72–90

    Article  CAS  PubMed  Google Scholar 

  • Hamm CW (2004c) Leitlinien: Akutes Koronarsyndrom (ACS). Teil 2: Akutes Koronarsyndrom mit ST-Hebung. Z Kardiol 93: 324–341

    Article  CAS  PubMed  Google Scholar 

  • Hamm CW, Heeschen C, Goldmann B et al. (1999) Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med 340: 1623–162

    Article  CAS  PubMed  Google Scholar 

  • Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, Bestehorn HP, Buttner HJ, Neumann FJ (2005) Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 111(20): 2560–4

    Article  CAS  PubMed  Google Scholar 

  • Kalla K, Christ G, Karnik R et al. (2006) Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI registry). Circulation 113: 2398–2405

    Article  PubMed  Google Scholar 

  • Kastrati A, Mehilli J, Neumann F-J et al. (2006) Abciximab in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment. The ISAR-REACT 2 Randomized Trial. JAMA 295: 1531–1538

    Article  CAS  PubMed  Google Scholar 

  • Keeley EC, Boura JA, Grines CL (2003) Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361: 13–20

    Article  PubMed  Google Scholar 

  • Mehta SR (2005) Efficacy and safety of fondaparinux compared to enoxaparin in 20.000 high risk patients with ACS without ST-elevation: the OASIS 5 Michelangelo programme. Presented at the European Society of Cardiology congress; September 4.–7. 2005; Stockholm, Sweden

    Google Scholar 

  • Neumann F-J, Kastrati A, Pogatsa-Murray G, Behilli J, Bollwein H, Bestehorn H-P, Schmitt C, Seyfarth M, Dirschinger J, Schömig A (2003) Evaluation of prolonged antithrombotic pretreatment (“cooling-off„ strategy) before intervention in patients with unstable coronary syndromes. JAMA 290: 1593–1599

    Article  CAS  PubMed  Google Scholar 

  • Pearson TA, Blair SN, Daniels SR et al. (2002) AHA Guidelines for Primary Prvention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. Circulation 106: 388–391

    Article  PubMed  Google Scholar 

  • PRISM-PLUS Study Investigators (1998) Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 338(21): 1488–97

    Article  Google Scholar 

  • PURSUIT Trial Investigators (1998) Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 339(7): 436–43

    Article  Google Scholar 

  • Roe MT, Parsons LS, Jr. Pollack CV et al. (2005) Quality of care by classification of myocardial infarction: treatment patterns for ST-Segment elevation vs non-ST-Segment elevation myocardial infarction. Arch Intern Med 165: 1630–1636

    Article  PubMed  Google Scholar 

  • Ross AM, Coyne KS, Reiner JS et al. (1999) A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial. J AM Coll Cardiol 34: 1954–1962

    Article  CAS  PubMed  Google Scholar 

  • Schömig A, Mehilli J, Antoniucci D, et al.; for the Beyond 12 hours Reperfusion AlternatiVe Evaluation (BRAVE-2) Trial Investigators (2005) Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. JAMA 293(23): 2865–72

    Article  PubMed  Google Scholar 

  • Smith SC, Allen J, Blair SN et al. (2006) AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation 113: 2363–2372

    Article  PubMed  Google Scholar 

  • Stone GW, Brodie BR, Griffin JJ et al. (1999) Clinical and aniographic follow-up after primary stenting in acute myocardial infarction: the primary angioplasty in myocardial infarction (PAMI) stent pilot trial. Circulation 99: 1548–1554

    CAS  PubMed  Google Scholar 

  • Stone GW, Moliterno DJ, Bertrand M et al. (2002) Impact of Clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoind coronary stenting. Circulation 105: 2347–2354

    Article  CAS  PubMed  Google Scholar 

  • Topol EJ; The GUSTO V investigators (2001) Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibitoren: the GUSTO V randomised trial. Lancet 357: 1905–1914

    Article  CAS  PubMed  Google Scholar 

  • Weaver WD, Simes RJ, Betriu A et al. (1997) Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quanitative review: JAMA 278: 2093–2098

    Article  CAS  PubMed  Google Scholar 

  • Zahn R, Schile R, Schneider S et al. (2001) Primary angioplasty versus no reperfusion therapy in patients with acute myocardial infarction and a prehospital delay of >12–24 hours: results from the pooled data of the maximal individual therapy in acute myocardial infarction (MITRA) registry and the myocardial infarction registry (MIR). J Invasive Cardiol 13: 367–372

    CAS  PubMed  Google Scholar 

  • Zijlstra F, de Boer MJ, Hoorntje JC, Reiffers S, Reiber JH, Suryapranata H (1993) A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 328: 680–684

    Article  CAS  PubMed  Google Scholar 

Literatur

  • Anand S, Yusuf S, Xie C et al.; Warfarin Antiplatelet Vascular Evaluation (WAVE) Trial Investigators (2007) Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 357: 217–227

    Article  CAS  PubMed  Google Scholar 

  • ATTC (Antiplatelet Trialists’ Collaboration) (1994) Collaborative Overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308: 81–106; Erratum in: BMJ 1994; 308: 1540

    Google Scholar 

  • Beebe HG, Dawson DL, Cutler BS, et al. (1999) A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 159: 2041–2050

    Article  CAS  PubMed  Google Scholar 

  • Berger JS, Rioncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL (2006) Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 295: 306–313. Erratum in: JAMA 2006; 295: 2002

    Article  CAS  PubMed  Google Scholar 

  • BOA (The Dutch Bypass Oral anticoagulants or Aspirin) Study Group (2000) Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial. Lancet 355: 346–351

    Article  Google Scholar 

  • CAPRIE-Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329–1339

    Article  Google Scholar 

  • Cosmi B, Conti E, Coccheri S (2001) Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication. Cochrane Database Syst Rev: CD001999

    Google Scholar 

  • Dawson DL, Cutler BS, Hiatt WR, Hobson RW 2nd, Martin JD, Bortey EB, Forbes WP, Strandness DE Jr (2000) A comparison of cilostatzol and pentoxifylline for treating intermittent claudication. Am J Med 109: 523–530

    Article  CAS  PubMed  Google Scholar 

  • de Vries SO, Hunink MG (1997) Results of aortic bifurcation grafts for aortoiliac occlusive disease: a meta-analysis. J Vasc Surg 26: 558–569

    Article  PubMed  Google Scholar 

  • Diehm C, Schuster A, Allenberg JR, Darius H, Haberl R, Lange S, Pittrow D, von Stritzky B, Tepohl G, Trampisch HJ (2004) High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis 172: 95–105

    Article  CAS  PubMed  Google Scholar 

  • Douglas JS Jr (2005) Role of adjunct pharmacologic therapy in the era of drug-eluting stents. Atheroscler Suppl 6: 47–52

    Article  CAS  PubMed  Google Scholar 

  • Elam MB, Heckman J, Crouse JR, Hunningshake DB, Herd JA, Davidson M, Gordon IL, Bortey EB, Forbes WP (1998) Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 18: 1942–1947

    CAS  PubMed  Google Scholar 

  • Gotho F, Tohgi H, Hirai S (2000) Cilostazol Stroke Prevention Study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 9: 147–157

    Article  Google Scholar 

  • Hiatt WR, Regensteiner JG, Creager MA et al. (2001) Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Am J Med 110: 616–622

    Article  CAS  PubMed  Google Scholar 

  • Hiatt WR, Money SR, Brass EP (2008) Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg. 47:330–336

    Article  PubMed  Google Scholar 

  • Hirsch AT, Haskal ZJ, Hertzer NR et al. (2005) ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic). Circulation 113: e463–654

    Google Scholar 

  • Hood SC, Moher D, Barber GG (1996) Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. CMAJ 155: 1053–1059

    CAS  PubMed  Google Scholar 

  • Kannel WB, McGee DL (1985) Update on some epidemiologic features of intermittent claudication: the Framingham Study. J Am Geriatr Soc 33: 13–18

    CAS  PubMed  Google Scholar 

  • Klein WM, van der Graaf Y, Seegers J, Moll FL, Mali WP (2004) Long-term cardiovascular morbidity, mortality, and reintervention after endovascular treatment in patients with iliac artery disease: The Dutch Iliac Stent Trial Study. nRadiology 232: 491–498

    Google Scholar 

  • Lederman RJ, Mendelsohn FO, Anderson RD et al.; TRAFFIC Investigators (2002) Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 359: 2053–2058

    Article  CAS  PubMed  Google Scholar 

  • Lehert P, Comte S, Gamand S, Brown TM (1994) Naftidrofuryl in intermittent claudication: a retrospective analysis. J Cardiovasc Pharmacol 23Suppl 3: 48–52

    Google Scholar 

  • Leng GC, Fowler B, Ernst E (2000) Exercise for intermittent claudication. Cochrane Database Syst Rev. (2): CD000990

    PubMed  Google Scholar 

  • Maxwell AJ, Anderson BE, Cooke JP (2000) Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar. Vasc Med 5: 11–19

    CAS  PubMed  Google Scholar 

  • Mohler ER 3rd, Hiatt WR, Creager MA (2003) Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation. 108: 1481–6

    Article  CAS  PubMed  Google Scholar 

  • Mondillo S, Ballo P, Barbati R, Guerini F, Ammaturo T, Agricole E, Pastore M, Borello F, Belcastro M, Picchi A, Nami R (2003) Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 114: 359–364

    Article  CAS  PubMed  Google Scholar 

  • Muntner P, Wildman RP, Reynolds K, Desalvo KB, Chen J, Fonseca V (2005) Relationship between HbA1c level and peripheral arterial disease. Diabetes Care 28: 1981–1987

    Article  PubMed  Google Scholar 

  • Muradin GS, Bosch JL, Stijnen T, Hunink MG (2001) Balloon dilation and stent implantation for treatment of femoropopliteal arterial disease: meta-analysis. Radiology 221: 137–145

    Article  CAS  PubMed  Google Scholar 

  • Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group (2007) Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 45 Suppl S: S5–67

    Article  CAS  PubMed  Google Scholar 

  • Otsuki M, Saito H, Xu X, Sumitani S, Kouhara K, Kurabayashi M, Kasayama S (2001) Cilostazol represses vascular cell adhesion molecule-1 gene transcription via inhibiting NF-kappaB binding to its recognition sequence. Atherosclerosis 158: 121–128

    Article  CAS  PubMed  Google Scholar 

  • Rajagopalan S, Mohler ER 3rd, Lederman RJ et al. (2003) Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108: 1933–1938

    Article  CAS  PubMed  Google Scholar 

  • Regensteiner JG, Ware JE Jr, McCarthy WJ, Zang P, Forbes WP, Heckmann J, Hiatt WR (2002) Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc 50: 1939–1946

    Article  PubMed  Google Scholar 

  • Ridker PM, Stampfer MJ, Rifai N (2001) Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285: 2481–2485

    Article  CAS  PubMed  Google Scholar 

  • Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, Jones DN (1997) Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 26: 517–538. Erratum in: J Vasc Surg 2001; 33: 805

    Article  CAS  PubMed  Google Scholar 

  • Salomaa V, Matei C, Aleksic N, Sansores-Garcia L, Folsom AR, Juneja H, Par E, Wu KK (2001) Cross-sectional association of soluble thrombomodulin with mild peripheral artery disease; the ARIC study. Atherosclerosis Risk in Communities. Atherosclerosis 157: 309–314

    CAS  Google Scholar 

  • Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH (2004) Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141: 421–431

    CAS  PubMed  Google Scholar 

  • Spengel F, Clement D, Boccalon H, Liard F, Brown T, Lehert P (2002) Findings of the Naftidrofuryl in Quality of Life (NIQOL) European study program. Int Angiol 21: 20–27

    CAS  PubMed  Google Scholar 

  • Takahashi S, Oida K, Fujiwara R, Maeda H, Hayashi S, Takai H, Tamai T, Nakai T, Miyabo S (1992) Effect of cilostazol, a cyclic AMP-phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol 20: 900–906

    Article  CAS  PubMed  Google Scholar 

  • Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG (2007) Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study. Eur Heart J 28: 354–362

    Article  CAS  PubMed  Google Scholar 

  • Woo SK, Kang WK, Kwon KI (2002) Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans. Clin Pharmacol Ther 71: 246–52

    Article  CAS  PubMed  Google Scholar 

Literatur

  • Ammaturo C, De RA, Salzano A et al. (2001) Intestinal infarction: report of 98 cases. Chir Ital 53: 57–64

    CAS  PubMed  Google Scholar 

  • Augsburger JJ, Magargal LE (1980) Visual prognosis following treatment of acute central retinal artery obstruction. Br J Ophthalmol 64: 913–7

    Article  CAS  PubMed  Google Scholar 

  • Batellier J, Kieny R (1990) Superior mesenteric artery embolism: eightytwo cases. Ann Vasc Surg 4: 112–6

    Article  CAS  PubMed  Google Scholar 

  • Bolderman R, Oyen R, Verrijcken A et al. (2006) Idiopathic renal infarction. Am J Med 119: 356–12

    Article  PubMed  Google Scholar 

  • Domanovits H, Paulis M, Nikfardjam M et al. (1999) Acute renal infarction. Clinical characteristics of 17 patients. Medicine (Baltimore) 78: 386–94

    Article  CAS  Google Scholar 

  • Eckstein HH (2003) Acute mesenteric ischemia. Resection or reconstruction? Chirurg 74: 419–31

    Article  PubMed  Google Scholar 

  • Feltgen N, Neubauer A, Jurklies B et al. (2006) Multicenter study of the European Assessment Group for Lysis in the Eye (EAGLE) for the treatment of central retinal artery occlusion: design issues and implications. EAGLE Study report no. 1. Graefes Arch Clin Exp Ophthalmol 244: 950–6

    Article  CAS  PubMed  Google Scholar 

  • Framme C, Spiegel D, Roider J et al. (2001) Central retinal artery occlusion. Importance of selective intra-arterial fibrinolysis. Ophthalmologe 98: 725–30

    CAS  Google Scholar 

  • Frippiat F, Donckier J, Vandenbossche P et al. (1996) Splenic infarction: report of three cases of atherosclerotic embolization originating in the aorta and retrospective study of 64 cases. Acta Clin Belg 51: 395–402

    CAS  PubMed  Google Scholar 

  • Guth AA, Pachter HL, Jacobowitz GR (1996) Rupture of the pathologic spleen: is there a role for nonoperative therapy? J Trauma 41: 214–8

    Article  CAS  PubMed  Google Scholar 

  • Hazanov N, Somin M, Attali M et al. (2004) Acute renal embolism. Fortyfour cases of renal infarction in patients with atrial fibrillation. Medicine (Baltimore) 83: 292–9

    Google Scholar 

  • Jaroch MT, Broughan TA, Hermann RE (1986) The natural history of splenic infarction. Surgery 100: 743–50

    CAS  PubMed  Google Scholar 

  • Lessman RK, Johnson SF, Coburn JW et al. (1978) Renal artery embolism: clinical features and long-term follow-up of 17 cases. Ann Intern Med 89: 477–82

    CAS  PubMed  Google Scholar 

  • Rivers SP, Veith FJ (2000) Nonocclusive mesenteric ischemia. In: Rutherford RB (ed) Vascular Surgery, 5th edition. Philadelphia: Saunders, p 1519–23

    Google Scholar 

  • Schumacher M, Schmidt D, Wakhloo AK (1991) Intra-arterial fibrinolysis in central artery occlusion. Radiologe 31: 240–3

    CAS  PubMed  Google Scholar 

  • Tsai FY, Wadley D, Angle JF et al. (1990) Superselective ophthalmic angiography for diagnostic and therapeutic use. Am J Neuroradiol 11: 1203–4

    CAS  PubMed  Google Scholar 

  • van Geloven AA, Biesheuvel TH, Luitse JS et al. (2000) Hospital admissions of patients aged over 80 with acute abdominal complaints. Eur J Surg 166: 866–871

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik III (Kardiologie und Kreislauferkrankungen), Universitätsklinikum Tübingen, Otfried-Müller-Straße 10, D-72076, Tübingen

    Dr. H. F. Langer

  2. Universitätsklinikum Tübingen, Otfried-Müller-Straße 10, D-72076, Tübingen

    Prof. Dr. M. Gawaz & Prof. Dr. A. E. May

  3. Praxis für Hämostaseologie und Transfusionsmedizin, Immermannstraße 65 a, D-40210, Düsseldorf

    Priv.-Doz. Dr. R. B. Zotz

  4. Institutes für Pharmakologie und Klinische Pharmakologie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität, Universitätsstraße 1, Geb. 22.21, D-40225, Düsseldorf

    Prof. Dr. K. Schrör

  5. Neurologische Klinik Medical Park, Thanngasse 15, D-83483, Bischofswiesen

    Prof. Dr. D. Sander

  6. Medizinische Klinik IV, Universitätsklinikum Tübingen, Otfried-Müller-Straße 10, D-72076, Tübingen

    Dr. J. Stock & Prof. Dr. B. Balletshofer

Authors
  1. Dr. H. F. Langer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. M. Gawaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Priv.-Doz. Dr. R. B. Zotz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Prof. Dr. K. Schrör
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Prof. Dr. D. Sander
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Prof. Dr. A. E. May
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dr. J. Stock
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Prof. Dr. B. Balletshofer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut für Experimentelle Hämatologie und Transfusionsmedizin, Universitätsklinikum Bonn, Sigmund-Freud-Straße 25, 53105, Bonn

    Bernd Pötzsch

  2. Kerckhoff Klinik, BenekeStraße 2-8, 61231, Bad Nauheim

    Katharina Madlener

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Langer, H.F. et al. (2010). Arterielle Thromboembolien. In: Pötzsch, B., Madlener, K. (eds) Hämostaseologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-01544-1_33

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-01544-1_33

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-01543-4

  • Online ISBN: 978-3-642-01544-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation